Palvella Therapeutics, Inc. (PVLA)
| Market Cap | 1.57B +494.4% |
| Revenue (ttm) | n/a |
| Net Income | -49.30M |
| EPS | -4.19 |
| Shares Out | 14.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 208,424 |
| Open | 103.34 |
| Previous Close | 105.05 |
| Day's Range | 101.29 - 110.35 |
| 52-Week Range | 20.20 - 151.18 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 229.00 (+109.71%) |
| Earnings Date | May 7, 2026 |
About PVLA
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for PVLA stock is "Strong Buy." The 12-month stock price target is $229.0, which is an increase of 109.71% from the latest price.
News
Palvella Therapeutics announces new data from TOIVA trial of Qtorin
Palvella Therapeutics (PVLA) announced new data from the Phase 2 TOIVA trial of Qtorin rapamycin in patients with cutaneous venous malformations were presented at the 83rd Annual Meeting of the…
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
100% of patients with bleeding at baseline demonstrated a statistically significant improvement on the Cutaneous Venous Malformations Investigator Global Assessment Bleeding scale (cVM-IGA Bleeding) a...
Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
Uplisting reflects Palvella's continued progress advancing potential first-in-disease therapies for serious, rare skin diseases and vascular malformations
Palvella Therapeutics initiated with an Overweight at Stephens
Stephens initiated coverage of Palvella Therapeutics (PVLA) with an Overweight rating and $220 price target Palvella is a clinical-stage biopharmaceutical company leveraging its Qtorin platform to tar...
Palvella Therapeutics reports Q1 EPS ($1.20) vs. (74c) last year
Reports Q1 cash, cash equivalents and short-term investments were $261.9M as of March 31, 2026. Reports Q1 R&D expenses $9.3M vs $4.1M last year. Reports Q1 G&A expenses $5.5M vs…
Palvella Therapeutics Earnings Call Transcript: Q1 2026
Positive phase III results for QTORIN rapamycin in mLM and a $230M financing position the company for a potential first FDA approval and U.S. launch in 2027, with a robust pipeline and strong physician support for first-line use.
Palvella Therapeutics Earnings release: Q1 2026
Palvella Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Palvella Therapeutics Quarterly report: Q1 2026
Palvella Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Palvella Therapeutics Slides: Q1 2026
Palvella Therapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
FDA Pre-New Drug Application (NDA) meeting granted for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, with meeting expected in second quarter of 2026; NDA submission on tr...
Palvella Therapeutics doses first patients in LOTU trial
Palvella Therapeutics (PVLA) announced that the first patients have been dosed in LOTU, a multicenter Phase 2 clinical trial designed to evaluate the safety and efficacy of Qtorin 3.9% rapamycin…
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas
Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA-approved therapies and an estimated more than 50,000 diagnosed patients in the U.S.
Palvella Therapeutics Proxy statement: Proxy filing
Palvella Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Palvella Therapeutics Proxy statement: Proxy filing
Palvella Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
WAYNE, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializ...
Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children's Hospital of Philadelphia to present clinical results on Wednesday, May 20, 2026, at 4:30 p.m. ET
Palvella Therapeutics Appoints John D. Doux, M.D.
Physician and seasoned life sciences investor with more than two decades of experience across clinical practice, biotechnology investing, and board leadership
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (Nasdaq: ARQT), where he led U.S. sa...
Palvella Therapeutics price target raised to $240 from $210 at Chardan
Chardan analyst Geulah Livshits raised the firm’s price target on Palvella Therapeutics (PVLA) to $240 from $210 and keeps a Buy rating on the shares. The company highlighted progress across…
Palvella Therapeutics price target raised to $210 from $200 at Oppenheimer
Oppenheimer raised the firm’s price target on Palvella Therapeutics (PVLA) to $210 from $200 and keeps an Outperform rating on the shares. The firm notes Palvella reported Q4 net loss…
Palvella Therapeutics Earnings Call Transcript: Q4 2025
Major milestones achieved in 2025 include positive phase III data, pipeline expansion, and a $230M financing, positioning the company for NDA submission and potential FDA approval in 2027. Strong cash reserves fully fund lead programs and commercial launch plans.
Palvella Therapeutics Annual report: Q4 2025
Palvella Therapeutics has published its Q4 2025 annual report on March 31, 2026.
Palvella Therapeutics Earnings release: Q4 2025
Palvella Therapeutics released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
New Drug Application (NDA) for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations (microcystic LMs) on track for planned submission in second half of 2026
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations
Review delineates differences in clinical strategies between microcystic and macrocystic lymphatic malformations to guide disease-specific clinical trial design and treatment approaches Manuscript emp...